

AN INNOVATIVE, EVIDENCE-BASED, ORAL NUTRITIONAL SUPPLEMENT DESIGNED TO MEET HIGH PROTEIN DEMANDS IN PATIENTS WITH DISEASE-RELATED MALNUTRITION

Are you overlooking simple solutions to address the challenging protein gaps?



Understanding the importance of early and assertive high protein intervention...

The prevalence of disease-related malnutrition (DRM) is consistently high across the patient journey¹;



1/4 hospital patients¹



1/3 oncology patients¹



1/3 community older patients¹



1/3 care home patients¹

Left unmanaged, DRM can lead to serious consequences which impact on a patient's recovery, independence and quality of life 2,3



Loss of muscle mass, strength and function⁴



Reduced mobility and independence⁴



Increased complications; infections and delayed wound healing³⁻⁵



Increased length of hospital stay (LoS) and cost of care³⁻⁵

Early and assertive provision of high-quality protein is an essential component of successful DRM intervention strategies^{4,6};



Daily Guideline Recommendations: (e.g. Polymorbid, Oncology, Geriatrics, Surgery)⁴⁻⁸

1-1.5g/kg/day

"High protein formulae contain 20% or more of total energy from protein"

ESPEN^{5,9}

Latest guidelines recommend significantly more protein compared to healthy populations⁴⁻⁸

Let's take a closer look at just how big the protein gap can be...

Case example*:



Admitted to hospital with suspected infection and fall at home

Age: 72 years*

Weight: 70kg*

BMI: 25kg/m^{2*}

Screened for malnutrition:

High risk

(NRS ≥3, or MUST ≥2)

Requirements (ESPEN ⁴⁻⁸)	Average intake*10
Protein (1-1.5g/kg/day): 70-105g protein/day	Protein intake: 47g/day
Energy: (25-30kcal/kg/day): 1750-2100kcal/day	Energy intake: 1211 kcal/day
Nutritional gap Up to 60g protein per day and up to 890 kcal per day (Values rounded off to nearest 10)	
Dietitian referral is indicated for full assessment and	

Before deciding on a suitable ONS prescription, first consider the common adherence barriers faced by patients with DRM²

individualized dietary intervention

Ensure assertive use of high protein oral nutritional

supplements (ONS) to optimise clinical outcome

Patients with DRM often struggle to finish a standard 200ml ONS¹¹⁻¹³ due to multiple barriers^{5,11};



- Poor appetite and early satiety
- Fatigue and shortness of breath
- Taste changes and nausea
- Limited variety of ONS flavours




Evidenced-based ONS specially designed to help meet the nutritional gap and overcome adherence barriers will lead to improved patient outcomes....


^{*}Data taken from Effort trial - average baseline values for patients at high risk of malnutrition in hospital**


Don't forget... Not all ONS are the same!

A high protein, high energy, low volume ONS can drive better adherence, and ultimately, better patient outcomes



High protein ONS result in improved outcomes such as increased grip strength, improved body composition, reduced complications (e.g. wound healing, infections) and LoS³







Fortimel Compact Protein

Nutricia's recommended first-line choice for patients with DRM

Fortimel Compact Protein is a high protein, high energy, low volume oral nutritional supplement for the dietary management of DRM



High protein content

18g per serving, 24% energy from protein



High quality protein¹⁴

100% cow's milk protein



High energy

306kcal per serving (2.4kcal/ml)



Low volume

125ml per serving

Backed by direct evidence base demonstrating efficacy on key clinical and health economic outcomes

11 flavours

High acceptability (96%)¹⁵ and adherence (90%)¹⁵

Improves protein intake¹⁶⁻¹⁸

Improves energy intake¹⁶⁻¹⁸

Increases body weight^{17,19}

Improves nutritional status^{15,20}

Improves muscle mass²¹ and supports improvement in strength and function**19

ONS does not impact negatively on food intake11



Improves health economic outcomes

>1000 Euro net saving per high-risk patient over 6 months***15

Hospital admissions reduced by 62% (P=.005)¹⁵

Length of stay reduced by 67% (P=.004)15

GP visits reduced by 25% (P=.006)¹⁵

Antibiotic prescriptions reduced by 39% (P=.04)¹⁵

Nutricia as your partner of choice for pioneering innovative patient-centric medical nutrition



Fortimel Compact Protein (125ml) is a Nutricia original innovation which was 'first of its kind' launched in the DRM medical nutrition market in 2012****.



Proudly developed to answer the demands for a high protein, high energy formula in a low volume, specially developed for patients suffering from DRM, in particular patients with poor appetite alongside high protein needs.



Nutricia support continuous investment in Fortimel Compact Protein evidence base, demonstrating efficacy in key clinical and health economic outcomes¹⁵⁻²¹.



Including 5 sensory adapted and tailored flavours, designed specifically for oncology patients with taste alterations, Fortimel Compact Protein range now offers one of the most extensive flavours ranges on the market**** (11 flavours in total).



Fortimel Compact Protein is a food for special medical purposes (FSMP), for the dietary management of disease-related malnutrition. It must be used under medical supervision only.

References

- http://medicalnutritionindustry.com/about/medical-nutrition/medical-nutrition-dossier
- [Accessed July 2022] Schuetz P, et al. Clin Nutr. 2020 Nov;39:3361-3368.
- Schuetz P, et al. Clin Nutr. 2021 Nov;59:5561-5568. Cawood AL, et al. Ageing Res Rev. 2012;11:278-96. Bauer J, et al. J Am Med Dir Assoc. 2013;14:542-59. Volkert D et al. Clin Nutr. 2022;41:958-989. Gomes F, et al. 2018;37:336-553. Muscaritoli M, et al. Clin Nutr. 2021;40:2898-2913.

- Weimann A, et al. Clin Nutr. 2017;36:623-650. Lochs H, et al. Clin Nutr. 2006;25:180-6. Schuetz P, et al. Lancet. 2019; 8:2312-2321. Hubbard GP, et al. Clin Nutr. 2012;31:293-312.

- Hubbard GP et al. Proc. Nutr. Soc. 2010; 69; OCE2: E164. 5.

- Hubbard GP et al. Proc. Nutr. Soc. 2010; 69; OCE2: E164. 5. Freeman R et al. Ageing Clin Exp Res. 2011; 23; 1:159 Phillips SM. Front Nutr. 2017;4:13. Brown F, et al. 2020;24:305-311. Ter Wee P, et al. 2016;20:944-951. Smith TR, et al. Nutrients. 2020;12:517. Frederiksen AKS, et al. Clin Nutr Open Sci. 2022;42:148-149. Grönstedt H, et al. J Am Med Dir Assoc. 2020;21:1229-1237. Grupińska J, et al. Nutrients. 2021;3:3549. Zietarska M, et al. Nutrients. 2021;1:1108.

- 22 http://malnutritionpathway.co.uk/downloads/Managing_Malnutrition.pdf [Accessed July 2022]

^{****} for patients at risk of, or malnourished who require products registered as FSMP in the EU.